Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

NCT05322499 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Esophagus Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Irinotecan
DRUG: Paclitaxel
DRUG: Paclitaxel-albumin
DRUG: Docetaxel
DRUG: Anlotinib

Sponsor

Zhejiang Cancer Hospital